Safety Outcomes of Apixaban Compared With Warfarin in Patients With End-Stage Renal Disease

Annals of Pharmacotherapy

Volumn 51, Issue 6, 2017, Pages 445-450

  Sarratt, Stefanie C ^a   Nesbit, Ross ^b   Moye, Robert ^b  

^a Southeast Clinical Oncology Research   (United States)

^b UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

apixaban; atrial fibrillation; bleeding; end stage renal disease; hemodialysis; hemorrhage; venous thromboembolism; warfarin

Indexed keywords

APIXABAN; HEMOGLOBIN; WARFARIN; ANTICOAGULANT AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CHADS2 SCORE; COHORT ANALYSIS; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; END STAGE RENAL DISEASE; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOPTYSIS; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; SIDE EFFECT; VENOUS THROMBOEMBOLISM; BLEEDING; CHEMICALLY INDUCED; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 85019040582     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028017694654     Document Type: Article

References (14)

1. Sohal AS, Gangji AS, Crowther MA. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res. 2006;118:417-422.
2. Shen J, Turakhia M, Winkelmayer W. Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? Curr Opin Nephrol Hypertens. 2012;21:600-606.
3. Limdi N, Beasley T, Baird M. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009;20:912-921.
4. January CT, Wann L, Alpert JS. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:2246-2280.
5. Olesen J, Lip G, Kamber A. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625-635.
6. Sood M, Larkina M, Thumma J. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. Kidney Int. 2013;84:600-608.
7. Shah M, Avgil T, Jackevicius C. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196-1203.
8. Eliquis (apixaban) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2015.
9. Pradaxa (dabigatran) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2015.
10. Xarelto (rivaroxaban) [package insert]. Gurabo, PR: Janssen Pharmaceuticals Inc; 2014.
11. Savaysa (edoxaban) [package insert]. Parsippany, NJ: Daiichi Sankyo; 2016.
12. Chang M, Yu Z, Shenker A. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56:637-645.
13. Wang X, Tirucherai G, Marbury T. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628-636.
14. Food and Drug Administration. Eliquis (apixaban) tablets safety labeling changes. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm384790.htm. Accessed June 26, 2016.